Biome Australia Ltd · ASX:BIO
Biome Australia — H1 FY26 Earnings Presentation
25 slides from Biome Australia's earnings presentation, Feb 25, 2026
Slide 1: H1 FY26 Results Company Presentation
For personal use only February 2026 H1 FY26 Results Jan&2024 Strategy Meeting Company Presentation Blair Vega Norfolk Founder & Managing Director
Slide 2: Biome Australia
Biome Australia For personal use only #1 fastest growing probiotic brand, ACTIVATED PROBIOTICS, in Australian pharmacy 100% of product range in growth. Full-margin growth without promotional discounting. Proprietary IP pipeline with first human clinical trial underway BMB18TM strain, 240-participant
Slide 3: H1 FY26 Financial Scorecard
H1 FY26 Financial Scorecard For personal use only Record results across all key metrics Revenue Adj. EBITDA Net Profit $12.40m $1.47m $1.18m +40% vs PCP 8th consecutive quarter +172% vs PCP Gross Margin Op. Cash Flow EPS 61.1% $2.09m 0.53c Achieved (1H25: 61.0%) $3.21m turnaround +165% vs PCP
Slide 4: Operating Leverage Now Visible
Operating Leverage Now Visible For personal use only Earnings growth significantly outpacing revenue growth Revenue & Cash Receipts ($m) EBITDA* (Adj) & Net Profit ($m) Revenue EBITDA Net Profit Cash Receipts +40% +100% +172% +62%
Slide 5: Market Opportunity
Market Opportunity Large, growing global market with significant runway in Australia and internationally For personal use only Global Probiotics Market Australian Probiotics Market ~US$75B+ ~A$600M estimated 2025, growing 7-8% CAGR estimated domestic market Dietary supplements the fastest growing seg
Slide 6: About Biome Australia
For personal use only About Biome Australia Biome Australia (ASX: BIO) is focused on becoming a global leader in the complementary medicine industry, offering clinically-proven, condition-specific probiotic products fueled by novel clinical research programs to cement and extend the evidence base of
Slide 7: A range of condition specific probiotics
For personal use only A range of condition specific probiotics Activated Probiotics has selected specific strains for various health conditions and aspects of health to create a range of precision probiotics 7
Slide 8: Selective formulations with clinically validated applications
For personal use only Selective formulations with clinically validated applications 8
Slide 9: Clinically Proven Product Range
Clinically Proven Product Range The majority of products are supported by published clinical trials on the finished product For personal use only Mood, Sleep & 3 RCTs on finished product Published in The Lancet Bone Health Depression Clinically proven for mood, sleep quality, 78% reduction in bone los
Slide 10: Clinical Evidence as Competitive Moat
Clinical Evidence as Competitive Moat The evidence base is what makes the practitioner model work. Without it, there is no recommendation. For personal use only Clinically Documented Condition-Specific Complementary to Strains Formulations Medical Treatment 18 products across two brands, each targeti
Slide 11: Adjunct Medication Opportunities
Adjunct Medication Opportunities Condition-specific range enables multiple products per patient, positioned alongside medical treatment For personal use only ATC medication category Medication volume Activated Probiotics product with adjunct opportunities July 2020–June 2021 10M per year General Anti
Slide 12: Market Position
Market Position For personal use only The fastest growing brand in the biggest category in pharmacy Community Pharmacy (ex CW) #1 Probiotic brand by revenue Fastest growing in category Terry White Chemmart #2 Total vitamins Fastest growing in category Priceline Pharmacy Significant headroom for furth
Slide 13: The Pull Model
The Pull Model For personal use only Full-margin growth without promotional discounting Traditional VMS Model Push Biome Model Pull Growth driven by promotional cycles and discounting Growth driven by practitioner recommendation Margin erosion as brands scale 61% gross margin achieved and maintained
Slide 14: The Practitioner Flywheel
The Practitioner Flywheel For personal use only Our competitive moat: practitioner endorsement drives category leadership 1 2 3 4 5 Practitioner Practitioner Pharmacy Scan Data Category Education Recommendation Purchase Validates Leadership Health-qualified Trusted endorsement ~2.5 units per Category
Slide 15: Training and Education Driven Sales Model
Training and Education Driven For personal use only Sales Model — Practitioner Only Unique Education and Service Model Drives Sales in Australia, UK and NZ Education and Service Support The Biome sales team is a mix of health qualified practitioner education consultants and territory managers Practit
Slide 16: Rolling Months and Quarterly Sales Revenue
For personal use only Rolling 12 Months and Quarterly Sales Revenue
Slide 17: Distribution growth and business development
For personal use only Distribution growth and business development ● Biome has grown its Australian distribution from 100 distribution points in 2019 to 7000+ in FY26 — the total addressable distribution market for Biome in our local market is ~12,000. ● Existing distribution (7000+) is expected to
Slide 18: Clinical & IP Pipeline
Clinical & IP Pipeline For personal use only Proprietary IP strategy building long-term competitive advantage Ethics Human Results & Discovery Preclinical Approval Trial Product Dev BMB18TM Lactobacillus plantarum BMB18TM Human Clinical Trial Trial Design: Randomised, double-blind, placebo-controlle
Slide 19: BMB18: Proprietary Strain Development
BMB18™: Proprietary Strain Development Lactobacillus plantarum BMB18 | 100% owned by Biome Australia | DSMZ registered For personal use only In Vitro Study Results Human Clinical Trial Completed by European research partner Commenced February 2026 Immune Modulation Design: Randomised, double-blind,
Slide 20: International Expansion
International Expansion For personal use only Four markets now contributing to revenue Established Australia Growing Canada 7000+ distribution points Fullscript (practitioner platform) TWC, Priceline, Symbion, API Ecotrend (national wholesale) Mecca, Go Vita Territory managers in ON, BC & Q Launched
Slide 21: H2 Outlook & Growth Catalysts
H2 Outlook & Growth Catalysts For personal use only Winter Immunity Campaign First major above-the-line national advertising campaign. Outdoor, digital, and co-branded activity with key retail partners. Timed to coincide with peak demand period. International Momentum Canada accelerating with Fullsc
Slide 22: Investment Case
Investment Case For personal use only Category Leader #1 fastest growing probiotic brand in Australia's biggest pharmacy category. 100% of range in growth. Premium Margin Model 61% gross margin achieved at scale without promotional discounting. Pull-based demand driven by practitioner endorsement su
Slide 23: Shaping the Industry
Shaping the Industry Biome plays an active role in advancing standards, regulation, and education across For personal use only the complementary medicine industry Complementary Medicines International Probiotics Australia (CMA) Association (IPA) Board Director Board Director CMA is the peak industry
Slide 24: Contact details
For personal use only Contact details Blair Norfolk, CEO Lauren Dwyer, CFO Email corporate@biomeaustralia.com Websites biomeaustralia.com activatedprobiotics.com.au
Slide 25: Disclaimer
Disclaimer For personal use only This presentation and the information contained within it (the “information”) has This presentation contains forward-looking statements, which may be identified by The recipient must, and agrees with the Company that it will, make its own been prepared solely for the